Literature DB >> 7964859

Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

B G van Engelen1, D J Miller, K D Pavelko, O R Hommes, M Rodriguez.   

Abstract

Spontaneous remyelination occurs in experimental models of demyelination and in patients with multiple sclerosis, although to a limited extent. This enables the search for factors that promote remyelination. Using the Theiler's virus model of central nervous system demyelination, promotion of remyelination was observed after passive transfer of CNS-specific antiserum and transfer of CNS-specific purified immunoglobulin. Mouse polyclonal immunoglobulin from normal non-syngeneic mice, comparable with the human immunoglobulin preparation, also promotes CNS remyelination in the Theiler's virus model of multiple sclerosis. These experimental findings further bridge the gap with a pilot study that suggests clinical improvement after polyclonal immunoglobulin administration, possibly due to remyelination, in some multiple sclerosis patients with stable, steroid-unresponsive optic neuritis. In view of these experimental and clinical data, the physiological role of myelin in demyelination and remyelination is discussed, and the role of IgG solely as a deleterious molecule in the pathophysiology of multiple sclerosis and experimental demyelination is addressed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964859      PMCID: PMC1016730          DOI: 10.1136/jnnp.57.suppl.65

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  MULTIPLE SCLEROSIS: THERAPEUTIC TRIALS OF CHLOROQUINE, SOLUBLE ASPIRIN, AND GAMMAGLOBULIN.

Authors:  H G MILLER; J B FOSTER; D J NEWELL; D D BARWICK; R A BREWIS
Journal:  Br Med J       Date:  1963-12-07

2.  High-dose intravenous immunoglobulin for multiple sclerosis.

Authors:  J Yan; J R Richert; M D Sirdofsky
Journal:  Lancet       Date:  1990-09-15       Impact factor: 79.321

3.  Stimulation of oligodendrocyte differentiation in culture by growth in the presence of a monoclonal antibody to sulfated glycolipid.

Authors:  R Bansal; A L Gard; S E Pfeiffer
Journal:  J Neurosci Res       Date:  1988 Oct-Dec       Impact factor: 4.164

4.  Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone.

Authors:  W F Blakemore
Journal:  J Neurol Sci       Date:  1973-09       Impact factor: 3.181

5.  Demyelination of the superior cerebellar peduncle in the mouse induced by cuprizone.

Authors:  W F Blakemore
Journal:  J Neurol Sci       Date:  1973-09       Impact factor: 3.181

6.  Antiserum-induced dissociation of myelinogenesis in vitro. An ultrastructural study.

Authors:  C S Raine; M Diaz; M Pakingan; M B Bornstein
Journal:  Lab Invest       Date:  1978-04       Impact factor: 5.662

7.  Immunoglobulins stimulate central nervous system remyelination: electron microscopic and morphometric analysis of proliferating cells.

Authors:  M Rodriguez
Journal:  Lab Invest       Date:  1991-03       Impact factor: 5.662

8.  Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; P Honegger; H Lassmann; J M Matthieu
Journal:  J Neurochem       Date:  1990-08       Impact factor: 5.372

9.  Immunoglobulins promote remyelination in the central nervous system.

Authors:  M Rodriguez; V A Lennon
Journal:  Ann Neurol       Date:  1990-01       Impact factor: 10.422

10.  Spinal cord lesions induced by antigalactocerebroside serum.

Authors:  F L Mastaglia; W M Carroll; A R Jennings
Journal:  Clin Exp Neurol       Date:  1989
View more
  11 in total

1.  New therapeutic perspectives for demyelinating retrobulbar optic neuritis.

Authors:  B Currò Dossi; A Amadori; C Cirafisi; S Lorusso; M Pasquinelli; M G Piscaglia; A Ravasio
Journal:  Ital J Neurol Sci       Date:  1998-02

Review 2.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

3.  Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Authors:  Gisa Ellrichmann; Ralf Gold; Ilya Ayzenberg; Min-Suk Yoon; Christiane Schneider-Gold
Journal:  Ther Adv Neurol Disord       Date:  2016-12-09       Impact factor: 6.570

Review 4.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 5.  Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.

Authors:  Namita Misra; Jagadeesh Bayry; Amal Ephrem; Suryasarathi Dasgupta; Sandrine Delignat; Jean-Paul Duong Van Huyen; Fabienne Prost; Sebastien Lacroix-Desmazes; Antonino Nicoletti; Michel D Kazatchkine; Srini V Kaveri
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

6.  Optic Neuritis.

Authors:  Laura J. Balcer
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

7.  Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination.

Authors:  K D Pavelko; B G van Engelen; M Rodriguez
Journal:  J Neurosci       Date:  1998-04-01       Impact factor: 6.167

8.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

9.  B-cell targeting agents in the treatment of multiple sclerosis.

Authors:  Tiffany J Braley; Benjamin M Segal
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 10.  Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives.

Authors:  Apostolia Tzekou; Michael G Fehlings
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.